<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7090474/results/search/test_trace/results.xml">
  <result pre="FcR activation may be a viable option for the urgent" exact="treatment" post="of pulmonary inflammation to prevent severe lung injury. Such"/>
  <result pre="treatment of pulmonary inflammation to prevent severe lung injury. Such" exact="treatment" post="may also be combined with systemic anti-inflammatory drugs or"/>
  <result pre="that of SARS-CoV; the acute lung injury caused by SARS-CoV" exact="infection" post="mainly results from aggressive inflammation initiated by viral replication"/>
  <result pre="viral replication (Wong et al.2004). Similar to SARS-CoV infection, SARS-CoV-2" exact="infection" post="also causes increased secretion of IL-1β, IFN-γ, IP-10, MCP-1,"/>
  <result pre="Nevertheless, the causes of these exuberant inflammatory responses in SARS-CoV-2" exact="infection" post="remain largely unknown. In this review, we attempt to"/>
  <result pre="studies of SARS-CoV, we separate the inflammatory responses in SARS-CoV-2" exact="infection" post="into primary and secondary responses. Primary inflammatory responses occur"/>
  <result pre="injury. Fig. 2 Fc receptor-mediated antibody-dependent enhancement (ADE) of viral" exact="infection" post="and inflammatory responses. A ADE occurs when antiviral neutralizing"/>
  <result pre="to the Fc receptor (FcR), leading to viral endocytosis and" exact="infection" post="of the target cells. The outcome is an increase"/>
  <result pre="exuberant pro-inflammatory cytokines and chemokines (Yang 2020). In addition, SARS-CoV-2" exact="infection" post="may also cause pyroptosis in macrophages and lymphocytes (Yang"/>
  <result pre="and Shedding ACE2-associated lung injury has been suggested in SARS-CoV" exact="infection" post="(Imai et al.2008; Kuba et al.2005); SARS-CoV S protein"/>
  <result pre="enzymatically active soluble ACE2 (sACE2) (Lambert et al.2005). Both SARS-CoV" exact="infection" post="and inflammatory cytokines such as IL-1β and TNF-α can"/>
  <result pre="to ACE2 to mediate NHL63-CoV entry (Haga et al.2008). HNL63-CoV" exact="infection" post="only causes the common cold, suggesting a potential pathogenic"/>
  <result pre="of anti-spike protein antibody at the acute stage of SARS-CoV" exact="infection" post="can actually cause severe acute lung injury that persists"/>
  <result pre="mechanism may be related to antibody-dependent enhancement (ADE) of viral" exact="infection" post="that occurs in some patients with early, sub-optimal antibody"/>
  <result pre="their interaction with FcR or other receptors, leading to enhanced" exact="infection" post="of target cells (Halstead and O’Rourke 1977; Haslwanter et"/>
  <result pre="possible underlying mechanism is likely antibody-dependent enhancement (ADE) of viral" exact="infection" post="that leads to persistent viral replication and inflammatory responses"/>
  <result pre="FcR activation may be a viable option for the urgent" exact="treatment" post="of pulmonary inflammation to prevent severe lung injury. Such"/>
  <result pre="treatment of pulmonary inflammation to prevent severe lung injury. Such" exact="treatment" post="may also be combined with systemic anti-inflammatory drugs or"/>
  <result pre="a descriptive studyLancet202010.1016/S0140-6736(20)30211-732112738 ClayCDonartNFomukongNKnightJBLeiWPriceLHahnFVan WestrienenJHarrodKSPrimary severe acute respiratory syndrome coronavirus" exact="infection" post="limits replication but not lung inflammation upon homologous rechallengeJ"/>
  <result pre="respiratory syndrome coronavirus and human coronavirus NL63J Virol2010841198120510.1128/JVI.01248-0919864379 GuJGongEZhangBZhengJGaoZZhongYZouWZhanJWangSXieZZhuangHWuBZhongHShaoHFangWGaoDPeiFLiXHeZXuDShiXAndersonVMLeongASMultiple organ" exact="infection" post="and the pathogenesis of SARSJ Exp Med200520241542410.1084/jem.2005082816043521 GuanWJNiZYHuYLiangWHOuCHeJLiuLShanHLeiCHuiDSCet al.Clinical"/>
  <result pre="SARSJ Exp Med200520241542410.1084/jem.2005082816043521 GuanWJNiZYHuYLiangWHOuCHeJLiuLShanHLeiCHuiDSCet al.Clinical characteristics of 2019 novel coronavirus" exact="infection" post="in ChinaMedRxiv202010.1101/2020.02.06.20020974 HagaSYamamotoNNakai-MurakamiCOsawaYTokunagaKSataTYamamotoNSasazukiTIshizakaYModulation of TNF-alpha-converting enzyme by the spike"/>
  <result pre="entryProc Natl Acad Sci U S A20081057809781410.1073/pnas.071124110518490652 HalsteadSBO’RourkeEJAntibody-enhanced dengue virus" exact="infection" post="in primate leukocytesNature197726573974110.1038/265739a0404559 HaslwanterDBlaasDHeinzFXStiasnyKA novel mechanism of antibody-mediated enhancement"/>
 </snippets>
</snippetsTree>
